Navigation Links
Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
Date:12/7/2012

tion and enhances insulin secretion, that confirmed the activity we observed in our preclinical studies," continued Dr. Bhanot.  "Given the unique mechanism of action and potentially favorable safety profile observed in the Phase 1 study, we believe that ISIS-GCGRRx could be valuable for diabetic patients with severe hyperglycemia who are not controlled with current treatments by not only controlling glucose, but also preserving pancreatic function, which would enhance endogenous insulin activity."

ISIS-GCCRRx
ISIS-GCCRRx targets the glucocorticoid receptor (GCCR) and is designed to reduce the effects of glucocorticoids, hormones that promote liver glucose production and fat storage in the liver and fat tissues.  Because excessive GCCR activity in the liver and fat is associated with obesity, insulin resistance and glucose intolerance, ISIS-GCCRRx has the potential to improve glycemic and lipid control in patients with type 2 diabetes.  "Reduction of GCCR in tissues other than the liver and fat, such as the brain, can result in many unwanted and potentially toxic side effects, as has been reported with small molecule inhibitors of GCCR.  Because ISIS-GCCRRx reduces GCCR activity only in liver and fat tissues, we avoid these unwanted side effects.  In preclinical studies, we demonstrated that antisense reduction of GCCR was limited to the liver and fat tissues and produced robust lowering of glucose and lipid levels.  Results from our ISIS-GCCRRx Phase 1 study were consistent with the liver- and fat-specific activity we observed in our preclinical studies, and also provided early encouraging data on the drug's therapeutic activity," concluded Dr. Bhanot.  "Given the mechanism of action, we believe that ISIS-GCCRRx could be particularly useful for diabetic patients with moderate to severe hyperglycemia who are also obese or have high levels of ch
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2. Arena Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference
3. Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms
4. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
5. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
6. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
7. Salix Pharmaceuticals Donates $500,000 To ASGEs IT&T Capital Campaign To Build A New State-of-the-Art GI Training Center
8. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
9. Double-digit Growth Rate of the Pharmaceuticals Industry in Asia Pacific Boosts the API Market, Finds Frost & Sullivan
10. Cadence Pharmaceuticals to Host Analyst and Investor Day
11. Nobel Prize Winner Bruce Beutler joins Sound Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... NEW YORK , Sept. 16, 2014 EHE ... exams with a nationwide physician network, today announced that ... has been named an EHE-certified preventive care center. Through ... Tarzana region now have greater access to ... "EHE is proud to add Dr. Abrams ...
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)...  Decision Resources Group finds that the rheumatoid arthritis (RA) disease-modifying ... over $18.2 billion in 2023 in the United States ... , Italy , Spain , ... . TNF-alpha inhibitors will remain the leading drug class in ... will be constrained and patient shares will decline due to the ...
Breaking Medicine Technology:EHE International Certifies David Abrams M.D. as Its Newest Partner 2QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3
... Newport Corporation (Nasdaq: NEWP ) today announced that it has ... to Dynasil Corporation (OTC Bulletin Board: DYSL), a provider of technology, ... markets. , , ... Hilger, based in Margate, UK, manufactures and sells a variety of ...
... N.Y. , July 20 As of ... standards applicable to devices that measure A1C (or glycated ... (NGSP) changed to +/-0.75% A1C, 95% CI, 4-10.0% A1C ... SELFCHECK devices, submits for annual NGSP certification each June ...
Cached Medicine Technology:Newport Corporation Completes Sale of Hilger Crystals to Dynasil Corporation 2Newport Corporation Completes Sale of Hilger Crystals to Dynasil Corporation 3New Standard of National Glycohemoglobin Standardization Program 2New Standard of National Glycohemoglobin Standardization Program 3
(Date:9/16/2014)... electronic activity monitors hold great promise in helping ... These increasingly sophisticated devices help the wearers improve ... bodily responses. This information is organized into companion ... the large and quickly growing market for these ... Branch at Galveston analyzed 13 of these activity ...
(Date:9/16/2014)... DC September 14, 2014 A ... everolimus-eluting stents (EES) and drug-eluting balloons (DEB) ... stents found that EES provided superior late ... , Findings were reported today at ... scientific symposium. Sponsored by the Cardiovascular Research ...
(Date:9/16/2014)... Seven heroes who have dramatically improved ... honored in New York City on November 6 by ... global recognition and funding program that honors individuals serving ... as the “Nobel Prize for Child Advocates,” this year’s ... that benefit children in countries around the world dealing ...
(Date:9/16/2014)... Tara Haelle HealthDay ... A new blood test is the first objective scientific way ... The test measures the levels of nine genetic indicators ... could also determine who will respond to cognitive behavioral therapy, ... and could show whether the therapy worked, Northwestern University researchers ...
(Date:9/16/2014)... Oncology (ASTRO) has selected C.M. Charlie Ma, PhD, Professor, ... Director of Medical Physics at Fox Chase Cancer ... members selected to receive the Fellow of ASTRO designation ... September 16, at the ASTRO,s 56th Annual Meeting in ... is a great honor and we are thrilled that ...
Breaking Medicine News(10 mins):Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Results of RIBS IV trial reported at TCT 2014 2Health News:World of Children® Award Announces 2014 Honorees 2Health News:World of Children® Award Announces 2014 Honorees 3Health News:World of Children® Award Announces 2014 Honorees 4Health News:World of Children® Award Announces 2014 Honorees 5Health News:World of Children® Award Announces 2014 Honorees 6Health News:World of Children® Award Announces 2014 Honorees 7Health News:World of Children® Award Announces 2014 Honorees 8Health News:Blood Test Spots Adult Depression: Study 2Health News:Blood Test Spots Adult Depression: Study 3
... Cancer Center, New York, and colleagues conducted a systematic ... harms of low-dose computerized tomography (LDCT) screening for lung ... "Most patients are diagnosed with advanced disease, resulting in ... "Renewed enthusiasm for lung screening arose with the advent ...
... - Treatment of obstructive sleep apnea (OSA) in children ... and executive function, according to a new study. ... in attention, cognition, and executive function," said lead author ... Sleep Center and University of Colorado Denver. "Our study ...
... More than 4.7 million Americans are bitten by dogs each ... than age 14, experts say. During National Dog Bite ... Pediatrics is joining with the American Veterinary Medical Association and ... They offer many tips to help parents protect their ...
... FRIDAY, May 18 (HealthDay News) -- One-third of homeless people in ... general population, a new study finds. It might seem that ... for weighing too little, according to the researchers at Harvard Medical ... Kingdom. But, the high rate of obesity among homeless people ...
... Since Sept. 11, it has become increasingly common ... or "infidels" to hell, but this has never ... State University professor who recently published a first-of-its-kind book ... Western writers believe condemnation and dehumanization of non-Muslims make ...
... May 18 (HealthDay News) -- Young people can easily buy ... wide range of advertising and marketing efforts from the alcohol ... the Center on Alcohol Marketing and Youth at the Johns ... alcohol messages, which may contribute to the 4,700 alcohol-related deaths ...
Cached Medicine News:Health News:Low-dose CT screening may benefit individuals at increased risk for lung cancer 2Health News:Treatment of childhood OSA reverses brain abnormalities 2Health News:Keeping Your Family Safe From Dog Bites 2Health News:One-Third of U.S. Homeless Population Is Obese: Study 2Health News:What does Islam say about the fate of others? 2Health News:Underage Drinkers Can Easily Order Alcohol From the Internet 2
Esophageal and Anorectal Solid State Catheter Adapter Cable for Polygraf ID...
... The ITREL 3 is a battery powered ... the U.S., ,Enterra™ Therapy is indicated ... vomiting associated with gastroparesis when conventional drug ... symptons for diabetic or idiopathic patients., ...
... diagnosis of influenza A and ... due to the availability of ... of influenza using Clearview Exact ... lead to reduced hospital stays, ...
... OMT test is a single use, qualitative, ... of antibodies to Human Immunodeficiency Virus Type ... human oral,mucosal transudate specimens. It is intended ... the clinical diagnosis of HIV,infection. This test ...
Medicine Products: